25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Anebulo Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Anebulo together

I guess you are interested in Anebulo Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Anebulo Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Anebulo Pharmaceuticals Inc

I send you an email if I find something interesting about Anebulo Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Anebulo (30 sec.)










1.2. What can you expect buying and holding a share of Anebulo? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.9%

What is your share worth?

Current worth
$0.07
Expected worth in 1 year
$-0.17
How sure are you?
11.8%

+ What do you gain per year?

Total Gains per Share
$-0.25
Return On Investment
-17.7%

For what price can you sell your share?

Current Price per Share
$1.40
Expected price per share
$1.25 - $1.82
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Anebulo (5 min.)




Live pricePrice per Share (EOD)
$1.40
Intrinsic Value Per Share
$-3.97 - $-4.65
Total Value Per Share
$-3.90 - $-4.57

2.2. Growth of Anebulo (5 min.)




Is Anebulo growing?

Current yearPrevious yearGrowGrow %
How rich?$1.8m$11.8m-$7.5m-175.8%

How much money is Anebulo making?

Current yearPrevious yearGrowGrow %
Making money-$1.9m-$2.8m$906.8k45.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Anebulo (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#757 / 944

Most Revenue
#872 / 944

Most Profit
#300 / 944

Most Efficient
#233 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Anebulo?

Welcome investor! Anebulo's management wants to use your money to grow the business. In return you get a share of Anebulo.

First you should know what it really means to hold a share of Anebulo. And how you can make/lose money.

Speculation

The Price per Share of Anebulo is $1.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anebulo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anebulo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.07. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anebulo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.08-6.1%-0.08-5.5%-0.11-7.8%-0.15-10.9%-0.15-10.9%
Usd Book Value Change Per Share-0.07-5.3%-0.06-4.4%-0.10-7.4%0.000.3%0.000.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.07-5.3%-0.06-4.4%-0.10-7.4%0.000.3%0.000.3%
Usd Price Per Share1.93-2.49-2.68-3.25-3.25-
Price to Earnings Ratio-5.69--8.96--6.43--10.21--10.21-
Price-to-Total Gains Ratio-26.15--42.53--26.90--49.86--49.86-
Price to Book Ratio26.36-17.38-6.28-8.43-8.43-
Price-to-Total Gains Ratio-26.15--42.53--26.90--49.86--49.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.4
Number of shares714
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.00
Usd Total Gains Per Share-0.060.00
Gains per Quarter (714 shares)-44.283.09
Gains per Year (714 shares)-177.1012.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-177-1870122
20-354-36402514
30-531-54103726
40-708-71804938
50-886-89506250
60-1063-107207462
70-1240-124908674
80-1417-142609886
90-1594-1603011198
100-1771-17801123110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.014.01.011.8%2.014.01.011.8%2.014.01.011.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.016.05.9%1.00.016.05.9%1.00.016.05.9%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.014.01.011.8%2.014.01.011.8%2.014.01.011.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Anebulo Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.074-0.062-16%-0.104+41%0.004-1814%0.004-1814%
Book Value Per Share--0.0730.166-56%0.457-84%0.375-80%0.375-80%
Current Ratio--3.4487.238-52%11.383-70%50.351-93%50.351-93%
Debt To Asset Ratio--0.2310.150+54%0.089+160%0.401-43%0.401-43%
Debt To Equity Ratio--0.3000.182+65%0.098+207%0.073+312%0.073+312%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Enterprise Value--50886094.81067867951.150-25%80969147.950-37%114139544.243-55%114139544.243-55%
Eps---0.085-0.076-10%-0.109+28%-0.152+79%-0.152+79%
Ev To Ebitda Ratio---5.942-9.681+63%-7.114+20%-15.003+152%-15.003+152%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.065-0.068+4%-0.100+53%-0.068+4%-0.068+4%
Free Cash Flow To Equity Per Share---0.065-0.069+5%-0.104+59%0.046-240%0.046-240%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.648--------
Intrinsic Value_10Y_min---3.971--------
Intrinsic Value_1Y_max---0.333--------
Intrinsic Value_1Y_min---0.327--------
Intrinsic Value_3Y_max---1.102--------
Intrinsic Value_3Y_min---1.050--------
Intrinsic Value_5Y_max---1.993--------
Intrinsic Value_5Y_min---1.841--------
Market Cap36306480.000-38%50051108.81064508855.400-22%69559325.700-28%84327143.788-41%84327143.788-41%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio19.122-38%26.36117.383+52%6.280+320%8.431+213%8.431+213%
Pe Ratio-4.124+27%-5.686-8.956+58%-6.432+13%-10.206+79%-10.206+79%
Price Per Share1.400-38%1.9302.488-22%2.682-28%3.252-41%3.252-41%
Price To Free Cash Flow Ratio-5.371+27%-7.404-9.276+25%-6.804-8%-13.154+78%-13.154+78%
Price To Total Gains Ratio-18.971+27%-26.152-42.527+63%-26.903+3%-49.858+91%-49.858+91%
Quick Ratio--2.4676.498-62%10.958-77%48.172-95%48.172-95%
Return On Assets---0.892-0.465-48%-0.226-75%-0.293-67%-0.293-67%
Return On Equity---1.159-0.566-51%-0.248-79%-0.303-74%-0.303-74%
Total Gains Per Share---0.074-0.062-16%-0.104+41%0.004-1806%0.004-1806%
Usd Book Value--1898715.0004295944.500-56%11847512.500-84%9721479.588-80%9721479.588-80%
Usd Book Value Change Per Share---0.074-0.062-16%-0.104+41%0.004-1814%0.004-1814%
Usd Book Value Per Share--0.0730.166-56%0.457-84%0.375-80%0.375-80%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Enterprise Value--50886094.81067867951.150-25%80969147.950-37%114139544.243-55%114139544.243-55%
Usd Eps---0.085-0.076-10%-0.109+28%-0.152+79%-0.152+79%
Usd Free Cash Flow---1689989.000-1763503.250+4%-2594009.000+53%-1751313.765+4%-1751313.765+4%
Usd Free Cash Flow Per Share---0.065-0.068+4%-0.100+53%-0.068+4%-0.068+4%
Usd Free Cash Flow To Equity Per Share---0.065-0.069+5%-0.104+59%0.046-240%0.046-240%
Usd Market Cap36306480.000-38%50051108.81064508855.400-22%69559325.700-28%84327143.788-41%84327143.788-41%
Usd Price Per Share1.400-38%1.9302.488-22%2.682-28%3.252-41%3.252-41%
Usd Profit---2200736.000-1980404.000-10%-2887271.500+31%-3479569.059+58%-3479569.059+58%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.074-0.062-16%-0.104+41%0.004-1806%0.004-1806%
 EOD+3 -5MRQTTM+8 -24YOY+16 -165Y+10 -2410Y+10 -24

3.3 Fundamental Score

Let's check the fundamental score of Anebulo Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.124
Price to Book Ratio (EOD)Between0-119.122
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.467
Current Ratio (MRQ)Greater than13.448
Debt to Asset Ratio (MRQ)Less than10.231
Debt to Equity Ratio (MRQ)Less than10.300
Return on Equity (MRQ)Greater than0.15-1.159
Return on Assets (MRQ)Greater than0.05-0.892
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Anebulo Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.768
Ma 20Greater thanMa 501.475
Ma 50Greater thanMa 1001.682
Ma 100Greater thanMa 2001.852
OpenGreater thanClose1.490
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

Fundamental data was last updated by Penke on 2024-12-05 12:25:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Anebulo earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anebulo to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.6%+108.6%
TTM--221.4%+221.4%
YOY--207.4%+207.4%
5Y--346.2%+346.2%
10Y--470.4%+470.4%
4.3.1.2. Return on Assets

Shows how efficient Anebulo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anebulo to the Biotechnology industry mean.
  • -89.2% Return on Assets means that Anebulo generated $-0.89 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is -89.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -46.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-89.2%TTM-46.5%-42.6%
TTM-46.5%YOY-22.6%-23.9%
TTM-46.5%5Y-29.3%-17.2%
5Y-29.3%10Y-29.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-89.2%-11.6%-77.6%
TTM-46.5%-12.0%-34.5%
YOY-22.6%-11.2%-11.4%
5Y-29.3%-12.6%-16.7%
10Y-29.3%-14.1%-15.2%
4.3.1.3. Return on Equity

Shows how efficient Anebulo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anebulo to the Biotechnology industry mean.
  • -115.9% Return on Equity means Anebulo generated $-1.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is -115.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -56.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-115.9%TTM-56.6%-59.3%
TTM-56.6%YOY-24.8%-31.8%
TTM-56.6%5Y-30.3%-26.3%
5Y-30.3%10Y-30.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-115.9%-14.5%-101.4%
TTM-56.6%-16.0%-40.6%
YOY-24.8%-14.6%-10.2%
5Y-30.3%-18.5%-11.8%
10Y-30.3%-19.2%-11.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Anebulo Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Anebulo is operating .

  • Measures how much profit Anebulo makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anebulo to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM--316.8%+316.8%
YOY--215.6%+215.6%
5Y--376.1%+376.1%
10Y--480.3%+480.3%
4.3.2.2. Operating Ratio

Measures how efficient Anebulo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM-3.198-3.198
YOY-3.247-3.247
5Y-4.651-4.651
10Y-6.419-6.419
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Anebulo Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Anebulo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.45 means the company has $3.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 3.448. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.238. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.448TTM7.238-3.790
TTM7.238YOY11.383-4.145
TTM7.2385Y50.351-43.113
5Y50.35110Y50.3510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4483.586-0.138
TTM7.2383.869+3.369
YOY11.3834.644+6.739
5Y50.3515.971+44.380
10Y50.3516.240+44.111
4.4.3.2. Quick Ratio

Measures if Anebulo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anebulo to the Biotechnology industry mean.
  • A Quick Ratio of 2.47 means the company can pay off $2.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 2.467. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.498. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.467TTM6.498-4.031
TTM6.498YOY10.958-4.460
TTM6.4985Y48.172-41.674
5Y48.17210Y48.1720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4673.093-0.626
TTM6.4983.392+3.106
YOY10.9584.304+6.654
5Y48.1725.953+42.219
10Y48.1726.435+41.737
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Anebulo Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Anebulo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anebulo to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Anebulo assets are financed with 23.1% credit (debt) and the remaining percentage (100% - 23.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 0.231. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.150. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.231TTM0.150+0.081
TTM0.150YOY0.089+0.061
TTM0.1505Y0.401-0.252
5Y0.40110Y0.4010.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2310.346-0.115
TTM0.1500.347-0.197
YOY0.0890.313-0.224
5Y0.4010.365+0.036
10Y0.4010.383+0.018
4.5.4.2. Debt to Equity Ratio

Measures if Anebulo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anebulo to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.0% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anebulo Pharmaceuticals Inc:

  • The MRQ is 0.300. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.182. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.300TTM0.182+0.118
TTM0.182YOY0.098+0.084
TTM0.1825Y0.073+0.109
5Y0.07310Y0.0730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3000.393-0.093
TTM0.1820.432-0.250
YOY0.0980.388-0.290
5Y0.0730.455-0.382
10Y0.0730.498-0.425
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anebulo generates.

  • Above 15 is considered overpriced but always compare Anebulo to the Biotechnology industry mean.
  • A PE ratio of -5.69 means the investor is paying $-5.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anebulo Pharmaceuticals Inc:

  • The EOD is -4.124. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.686. Based on the earnings, the company is expensive. -2
  • The TTM is -8.956. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.124MRQ-5.686+1.561
MRQ-5.686TTM-8.956+3.270
TTM-8.956YOY-6.432-2.523
TTM-8.9565Y-10.206+1.250
5Y-10.20610Y-10.2060.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.124-2.180-1.944
MRQ-5.686-2.507-3.179
TTM-8.956-3.153-5.803
YOY-6.432-3.242-3.190
5Y-10.206-5.992-4.214
10Y-10.206-6.690-3.516
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anebulo Pharmaceuticals Inc:

  • The EOD is -5.371. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.404. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.276. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.371MRQ-7.404+2.033
MRQ-7.404TTM-9.276+1.872
TTM-9.276YOY-6.804-2.472
TTM-9.2765Y-13.154+3.878
5Y-13.15410Y-13.1540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.371-2.879-2.492
MRQ-7.404-3.276-4.128
TTM-9.276-3.669-5.607
YOY-6.804-4.485-2.319
5Y-13.154-8.015-5.139
10Y-13.154-9.197-3.957
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Anebulo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 26.36 means the investor is paying $26.36 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Anebulo Pharmaceuticals Inc:

  • The EOD is 19.122. Based on the equity, the company is expensive. -2
  • The MRQ is 26.361. Based on the equity, the company is expensive. -2
  • The TTM is 17.383. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD19.122MRQ26.361-7.239
MRQ26.361TTM17.383+8.977
TTM17.383YOY6.280+11.103
TTM17.3835Y8.431+8.952
5Y8.43110Y8.4310.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD19.1221.964+17.158
MRQ26.3612.056+24.305
TTM17.3832.388+14.995
YOY6.2802.460+3.820
5Y8.4313.697+4.734
10Y8.4314.324+4.107
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Anebulo Pharmaceuticals Inc.

4.8.1. Institutions holding Anebulo Pharmaceuticals Inc

Institutions are holding 28.176% of the shares of Anebulo Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-3022NW, LP20.69278.6827536629000
2024-09-30LVW Advisors, LLC2.47190.1575641039-1000-0.1558
2024-09-30Nantahala Capital Management, LLC1.97070.0499511073-511073-50
2024-09-30Morgan Stanley - Brokerage Accounts1.53940.0001399219-399219-50
2024-09-30Ikarian Capital, LLC0.60870.042515786200
2024-09-30Vanguard Group Inc0.59401540361630.1059
2024-09-30Geode Capital Management, LLC0.33850877903648271.1039
2024-09-30BOOTHBAY FUND MANAGEMENT, LLC0.07320.00081897800
2024-06-30BlackRock Inc0.014503761-288-7.1129
2024-09-30Tower Research Capital LLC0.01040.00012694-606-18.3636
2024-09-30UBS Group AG0.002907637630
2024-06-30Bank of America Corp0.0003065650
2024-06-30Royal Bank of Canada0.00020511334.2105
2024-09-30JPMorgan Chase & Co009-1-10
2024-06-30Susquehanna International Group, LLP000-25253-100
2024-06-30Wells Fargo & Co000-62-100
Total 28.31748.93367343630-900016-12.3%

4.9.2. Funds holding Anebulo Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv0.4666012100000
2024-09-30Fidelity Extended Market Index0.21070.0003546291023323.0494
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.12740.00013303600
2024-09-30Fidelity Total Market Index0.0568014728147280
2024-09-30Fidelity Series Total Market Index0.0457011840110031314.5759
2024-09-30Northern Trust Extended Eq Market Idx0.02550.0002661600
2024-09-30NT Ext Equity Mkt Idx Fd - L0.02550.0002661600
2024-09-30Fidelity Nasdaq Composite Index0.01580410800
2024-11-27iShares Micro-Cap ETF0.01360.0005351500
2024-09-30Spartan Extended Market Index Pool E0.00510.0001133217915.5247
2024-09-30Spartan Total Market Index Pool E0.00420109400
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00390.0002102120.1963
2024-09-301290 VT Micro Cap K0.00140.000436600
2024-10-31State St US Extended Mkt Indx NL Cl C0.0008020000
2024-06-30SSgA U.S. Total Market Index Strategy0.00030822441.3793
2024-09-30Fidelity U.S. Equity Index Ins Trust0.000205900
Total 1.00350.002260242+36169+13.9%

5.3. Insider Transactions

Insiders are holding 64.221% of the shares of Anebulo Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-12-17Aron R EnglishBUY4006.59
2021-12-14Aron R EnglishBUY4125.89
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets2,468
Total Liabilities569
Total Stockholder Equity1,899
 As reported
Total Liabilities 569
Total Stockholder Equity+ 1,899
Total Assets = 2,468

Assets

Total Assets2,468
Total Current Assets1,963
Long-term Assets505
Total Current Assets
Cash And Cash Equivalents 1,404
Other Current Assets 558
Total Current Assets  (as reported)1,963
Total Current Assets  (calculated)1,963
+/-0
Long-term Assets
Long-term Assets Other 505
Long-term Assets  (as reported)505
Long-term Assets  (calculated)505
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities569
Long-term Liabilities317
Total Stockholder Equity1,899
Total Current Liabilities
Accounts payable 252
Other Current Liabilities 317
Total Current Liabilities  (as reported)569
Total Current Liabilities  (calculated)569
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)317
Long-term Liabilities  (calculated)0
+/- 317
Total Stockholder Equity
Common Stock26
Retained Earnings -67,604
Other Stockholders Equity 69,477
Total Stockholder Equity (as reported)1,899
Total Stockholder Equity (calculated)1,899
+/-0
Other
Cash and Short Term Investments 1,404
Common Stock Shares Outstanding 25,933
Liabilities and Stockholders Equity 2,468
Net Debt -1,404
Net Working Capital 1,393



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-30
> Total Assets 
0
2,611
2,611
4,291
21,653
20,500
18,964
17,248
15,579
19,815
16,888
14,433
11,670
9,048
7,501
5,996
4,073
2,468
2,4684,0735,9967,5019,04811,67014,43316,88819,81515,57917,24818,96420,50021,6534,2912,6112,6110
   > Total Current Assets 
2,509
2,509
2,509
3,899
19,986
20,500
18,964
17,248
14,548
19,815
16,888
14,433
11,670
9,048
6,816
5,371
3,508
1,963
1,9633,5085,3716,8169,04811,67014,43316,88819,81514,54817,24818,96420,50019,9863,8992,5092,5092,509
       Cash And Cash Equivalents 
0
2,480
2,480
3,307
19,986
19,208
18,009
16,548
14,548
19,214
16,355
14,165
11,247
8,521
6,645
5,147
3,094
1,404
1,4043,0945,1476,6458,52111,24714,16516,35519,21414,54816,54818,00919,20819,9863,3072,4802,4800
       Net Receivables 
0
0
0
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000023000
       Other Current Assets 
0
29
29
569
1,668
1,293
955
701
1,031
602
533
268
423
527
343
447
414
558
5584144473435274232685336021,0317019551,2931,66856929290
   > Long-term Assets 
0
102
102
393
1,668
0
0
0
1,031
0
0
0
423
0
685
625
565
505
50556562568504230001,0310001,6683931021020
       Long-term Assets Other 
0
102
102
393
0
0
0
0
0
0
0
0
423
0
685
625
565
505
5055656256850423000000003931021020
> Total Liabilities 
0
3,330
3,330
13,727
242
608
50
86
513
698
1,372
1,491
1,069
717
1,014
1,010
261
569
5692611,0101,0147171,0691,4911,372698513865060824213,7273,3303,3300
   > Total Current Liabilities 
354
354
354
293
242
608
50
86
513
698
1,372
1,491
1,069
717
1,014
1,010
261
569
5692611,0101,0147171,0691,4911,3726985138650608242293354354354
       Short-term Debt 
0
209
209
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002092090
       Short Long Term Debt 
0
209
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002090
       Accounts payable 
84
84
84
82
110
494
43
83
381
523
347
571
535
566
319
385
156
252
252156385319566535571347523381834349411082848484
       Other Current Liabilities 
0
60
60
211
132
114
7
3
132
175
1,026
920
534
151
695
625
104
317
3171046256951515349201,0261751323711413221160600
   > Long-term Liabilities 
0
2,976
2,976
13,434
110
494
43
83
381
523
1,026
571
534
151
695
625
0
317
31706256951515345711,026523381834349411013,4342,9762,9760
       Other Liabilities 
0
0
0
10,458
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000010,458000
> Total Stockholder Equity
0
-719
-719
-9,436
21,412
19,893
18,914
17,163
15,067
19,117
15,516
12,942
10,601
8,331
6,487
4,985
3,813
1,899
1,8993,8134,9856,4878,33110,60112,94215,51619,11715,06717,16318,91419,89321,412-9,436-719-7190
   Common Stock
2
13
13
13
23
23
23
23
23
26
26
26
26
26
26
26
26
26
26262626262626262623232323231313132
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 00000000000000-2,975,752000
   Capital Surplus 
0
38
0
84
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000840380
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
36
36
84
60,033
60,067
60,161
60,286
60,513
67,173
67,399
67,622
67,778
67,989
68,862
69,013
69,190
69,477
69,47769,19069,01368,86267,98967,77867,62267,39967,17360,51360,28660,16160,06760,0338436360



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-8,309
Operating Income-8,309-8,309
 
Operating Expense (+$)
Research Development3,549
Selling General Administrative4,755
Selling And Marketing Expenses5
Operating Expense8,3098,309
 
Net Interest Income (+$)
Interest Income249
Interest Expense-151
Other Finance Cost-0
Net Interest Income98
 
Pretax Income (+$)
Operating Income-8,309
Net Interest Income98
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-8,202-8,416
EBIT - interestExpense = -8,460
-8,202
-8,050
Interest Expense151
Earnings Before Interest and Taxes (EBIT)-8,309-8,050
Earnings Before Interest and Taxes (EBITDA)-8,050
 
After tax Income (+$)
Income Before Tax-8,202
Tax Provision-0
Net Income From Continuing Ops-8,202-8,202
Net Income-8,202
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses8,309
Total Other Income/Expenses Net107-98
 

Technical Analysis of Anebulo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anebulo. The general trend of Anebulo is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anebulo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anebulo Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.72 < 1.8 < 1.82.

The bearish price targets are: 1.25.

Tweet this
Anebulo Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anebulo Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anebulo Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anebulo Pharmaceuticals Inc. The current macd is -0.0700657.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anebulo price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Anebulo. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Anebulo price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Anebulo Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAnebulo Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anebulo Pharmaceuticals Inc. The current adx is 13.55.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Anebulo shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Anebulo Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anebulo Pharmaceuticals Inc. The current sar is 1.60218859.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Anebulo Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anebulo Pharmaceuticals Inc. The current rsi is 40.77. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Anebulo Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAnebulo Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anebulo Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anebulo price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Anebulo Pharmaceuticals Inc Daily Stochastic Oscillator ChartAnebulo Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anebulo Pharmaceuticals Inc. The current cci is -95.89324935.

Anebulo Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAnebulo Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anebulo Pharmaceuticals Inc. The current cmo is -19.56341535.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Anebulo Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAnebulo Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anebulo Pharmaceuticals Inc. The current willr is -71.42857143.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Anebulo is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Anebulo Pharmaceuticals Inc Daily Williams %R ChartAnebulo Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anebulo Pharmaceuticals Inc.

Anebulo Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anebulo Pharmaceuticals Inc. The current atr is 0.14233561.

Anebulo Pharmaceuticals Inc Daily Average True Range (ATR) ChartAnebulo Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anebulo Pharmaceuticals Inc. The current obv is -210,678.

Anebulo Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAnebulo Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anebulo Pharmaceuticals Inc. The current mfi is 39.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Anebulo Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAnebulo Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anebulo Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Anebulo Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anebulo Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.768
Ma 20Greater thanMa 501.475
Ma 50Greater thanMa 1001.682
Ma 100Greater thanMa 2001.852
OpenGreater thanClose1.490
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Anebulo with someone you think should read this too:
  • Are you bullish or bearish on Anebulo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anebulo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anebulo Pharmaceuticals Inc

I send you an email if I find something interesting about Anebulo Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Anebulo Pharmaceuticals Inc.

Receive notifications about Anebulo Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.